Hepatitis C: Standard of Treatment and What to Do for Global Elimination

Area of Science:

• Hepatology and Virology
• Public Health and Epidemiology

Background:

• Hepatitis C virus (HCV) infection significantly contributes to global morbidity and mortality, causing cirrhosis, liver cancer, and liver-related deaths.
• Current direct-acting antiviral (DAA) drugs offer high efficacy and safety for treating chronic liver disease and reducing infection spread.

Purpose of the Study:

• To analyze effective models and strategies for achieving the World Health Organization's (WHO) 2030 global elimination goals for HCV infection.
• To identify key areas for improvement in screening, diagnosis, treatment selection, and patient care linkage.

Main Methods:

• Review of existing literature and global health strategies related to HCV elimination.
• Analysis of requirements for screening, diagnosis, and treatment selection models.
• Examination of linkage to care models for at-risk and marginalized populations.

Main Results:

• Effective screening strategies are required for both high-risk groups and the general population.
• Fast and effective diagnostic models for liver disease are essential.
• Cost-effective selection of direct-acting antiviral drugs is crucial.
• Tailored linkage to care models are needed for at-risk and marginalized populations.
• Development of an effective HCV vaccine remains an unmet need.

Conclusions:

• Achieving global HCV elimination by 2030 requires a multi-faceted approach encompassing screening, diagnosis, cost-effective treatment, and targeted care.
• Further research and development are necessary, particularly for vaccine strategies and optimized linkage to care.
• Addressing the needs of vulnerable populations is critical for successful elimination efforts.